- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02064205
Appetite Suppression Trial With Polydextrose
A Double Blind, Placebo Controlled, Randomized, Cross-over Study to Assess the Effects of Polydextrose on Appetite Suppression and Its Mechanisms of Action in Healthy Women With a Normal Weight and Overweight Female Participants.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Polydextrose is a well-tolerated, low calorie glucose polymer (4kJ/g) that can be easily incorporated into various food applications to replace sugar and fat (Auerbach et al., 2007). Polydextrose is poorly digested in the upper gastrointestinal tract and therefore shows fiber-like properties. The addition of polydextrose to foods may increase the satiating properties of foods.
Previous studies have shown that:
- Consuming polydextrose-containing preloads (6.25 - 25.0 g polydextrose) resulted in a significant lower energy intake at lunch compared to the control (Astbury et al., 2013; Ranawana et al., 2013; Hull et al., 2012; King et al., 2005).
- Polydextrose is able to modify appetite ratings at low (6.25 - 12.5 g polydextrose) (Hull et al., 2012) and high doses (56.7 g/d) (Konings et al., 2013).
- Polydextrose (15.0 g) induced enhanced GLP-1 response after a high-fat meal in obese participants (Tiihonen et al., 2012).
Therefore, it is hypothesized that with the consumption of 12.5 g polydextrose as compared with the placebo, appetite will be suppressed, resulting in:
- a lower consumption at lunch (energy intake at lunch)
- change in appetite scores (VAS)
- change in satiety hormones (CCK, PYY, GLP-1, ghrelin)
- change in glucose and insulin
- change in stomach emptying rate
- change in gastric wellbeing
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9713AG
- QPS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, female participants aged 20-45 years inclusive
- BMI: 20-30 kg/m2 inclusive
- Written consent regarding participation after full information regarding all details of the study
- Normal Dutch eating habits (consuming mostly three main meals per day; used to eat bread for lunch)
Exclusion Criteria:
- Pregnancy
- On-going or recent treatment for diabetes, hypertension, coronary heart disease, psychiatric conditions, inflammatory chronic disease - rheumatoid arthritis, Crohn Disease, ulcerous colitis, chronic constipation, eating disorders, or any disease condition which interferes with ADME of the investigational product
- Reported postmenopausal
- Having menstruation problems, e.g. PCOS
- Reported to be on a slimming diet or other dietary treatment (currently or during last two months, like vegetarian diet, lactose restricted diet etc.)
- Aversion towards products (yoghurt) provided in the study
- On-going use of any slimming preparations
- Any kind of dysfunction of digestive tract, food allergy, chronic constipation, recent/actual gastroenteritis
- Restrained eaters (score DEBQ >3.4)
- Participants consuming more than 23g of dietary fiber per day - P75 according to the Dutch National Food Consumption Survey - (as assessed with a general short questionnaire which gives estimation on the fiber intake. Exact fiber intake will not be calculated)
- Smoker in the last 3 months
- Heavy coffee drinkers (more than 6 cups a day)
- High level of physical activity: Participants who perform more than 3 hours of intense training/sport activity per week (this will not include normal cycling transport)
- Heavy alcohol consumers, no more than 14 units per week (1 unit represents 1 standard glass/portion of alcohol, independent of the type of alcoholic drink).
Remark:
When enough subjects are eligible (> 32), the women with the highest BMI will be selected to participate. At least 50% of the subjects will have a BMI ranging of 25-30. Also at least 50% of the women will be in the age range of 25-45 years. When more than 32 subjects are eligible the eldest subjects will be included.
With respect to eligibility of the subjects:
the BMI criterion always comes for age criterion, meaning that overweight is stressed to be of more importance for this study than age. Overweight will always come first, even when already > 50% of the women with a BMI 25-30 have been included. In this way the overweight group of women will be studied as much as possible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: polydextrose or glucose syrup at breakfast
Breakfast with pre-load four hours before lunch
|
Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch.
Also yogurt with control (glucose syrup) is tested for its satiating effect.
Other Names:
Glucose syrup is used a control product for the polydextrose
|
|
Placebo Comparator: Pre-load with yogurt and polydextrose or glucose later
Breakfast without pre-load.
Pre-load with yogurt provided 1.5h before lunch.
|
Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch.
Also yogurt with control (glucose syrup) is tested for its satiating effect.
Other Names:
Glucose syrup is used a control product for the polydextrose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Energy Intake at an ad Libitum Lunch on a Test-day in Normal Weight and Overweight Women.
Time Frame: Four hours or 1.5 hour after consumption of a pre-load at up to day 22
|
Yogurt with a polydextrose (fiber with satiating effect) is consumed in the morning with breakfast or later in the morning.
The satiating effect of the addition of polydextrose is tested on the amount of food consumed with lunch four hours or 1.5h later.
|
Four hours or 1.5 hour after consumption of a pre-load at up to day 22
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Appetite Suppressive Effect of Polydextrose During Meal Consumption (Satiation) and Satiety (After Food Consumption)
Time Frame: one day
|
The appetite suppressive effect of polydextrose measured with Visual Analogue rating Scales (VAS).
The AUCs were calculated for the scores obtained before - first score after meal intake (satiation) and for score after meal till start of next meal (in between meals, satiety).
The VAS scores ranged from 0-100 for hunger and fullness (HUNGER: 0 = no hunger , 100 = very hungry; FULNESS: 0 = not full, 100 = very full)
|
one day
|
|
Evaluate Effect of Pre-load on Satiety Hormones in Normal Weight and Overweight Women.
Time Frame: Four hour curves (t=0, 30, 60, 90, 150 and 240 min) of day 01, day 08, day 15 and day 22.
|
The satiety hormones CCK, GLP-1, ghrelin and PYY are measured before (t=0) and after breakfast consumption (at t=30, 60, 90, 150, 240) . This is done on day 01, day 08, day 15 and day 22 with at least four days wash-out in-between. The satiety hormones were only measured in the conditions when the pre-load was given with breakfast (condition A and B). Area under the curves were calculated of the time curves. |
Four hour curves (t=0, 30, 60, 90, 150 and 240 min) of day 01, day 08, day 15 and day 22.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Naguib Muhsen, MD, QPS, The Netherlands
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JZ PDX Satiety
- WM-01-2014 (Other Identifier: QPS, The Netherlands)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Weight
-
Oslo University HospitalMayo Clinic; Sorlandet Hospital HF; The Hospital of Vestfold; University of TwenteActive, not recruiting
-
Fred Hutchinson Cancer CenterCompletedWeight Loss | Weight, BodyUnited States
-
Pusan National University HospitalCompletedWeight Change, Body
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Erik Ramirez LopezCompletedWeight Loss | Body CompositionMexico
-
Virta HealthCompleted
-
University of TennesseeMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases...CompletedSmoking Cessation | Weight Change, BodyUnited States
-
University of CopenhagenCompleted
-
North Dakota State UniversityThe Cleveland Clinic; Neuropsychiatric Research InstituteUnknown
-
University of LeedsDietary Assessment LtdCompletedWeight Loss | Colorectal Surgery | Weight Change, Body | Gastroenterology SurgeryUnited Kingdom
Clinical Trials on 12.5 g polydextrose
-
Clinical Nutrition Research Center, Illinois Institute...Completed
-
KGK Science Inc.DuPont Nutrition and HealthCompletedFunctional ConstipationCanada
-
DaniscoSprim Advanced Life SciencesTerminatedFunctional ConstipationItaly
-
University Hospital, ToulouseSociété nationale française de gastro-entérologieRecruitingHepatic EncephalopathyFrance
-
Universidade Federal FluminenseCompleted
-
Kaleido BiosciencesCompleted
-
Clinical Nutrition Research Center, Illinois Institute...Completed
-
Tate & LyleOy Foodfiles LtdCompletedConstipation | Gastrointestinal Dysfunction
-
Newcastle UniversityNorthumbria Healthcare NHS Foundation TrustUnknownColorectal CancerUnited Kingdom
-
Maastricht University Medical CenterTate and Lyle Ingredients FranceCompletedObesity | Type 2 Diabetes MellitusNetherlands